Journal
DISEASE MODELS & MECHANISMS
Volume 11, Issue 5, Pages -Publisher
COMPANY BIOLOGISTS LTD
DOI: 10.1242/dmm.032292
Keywords
Breast cancer; Chemotherapy; Resistance; TCF4; Xenograft; Transcription factor; Patient-derived xenograft
Categories
Funding
- Asociacion Espanola Contra el Cancer (AECC)
- Generalitat de Catalunya [SGR 2014-364, 2017-449]
- Ministerio de Economia y Competitividad [SAF2013-45836-R, SAF2017-87811R]
- European Regional Development Fund (ERDF/FEDER Una manera de hacer Europa)
- Instituto de Salud Carlos III [PIE13/00022-ONCOPROFILE, FIS PI13/01339, PI15/00854, PI16/01898, RTICC RD12/0036/0008]
- Fundacion Mutua Madrilena [AP150932014]
- Department of Education of the Basque Government [PRE-2017-1-0100]
Ask authors/readers for more resources
Understanding the mechanisms of cancer therapeutic resistance is fundamental to improving cancer care. There is clear benefit from chemotherapy in different breast cancer settings; however, knowledge of the mutations and genes that mediate resistance is incomplete. In this study, by modeling chemoresistance in patientderived xenografts (PDXs), we show that adaptation to therapy is genetically complex and identify that loss of transcription factor 4 (TCF4; also known as ITF2) is associated with this process. A triple-negative BRCA1-mutaied PDX was used to study the genetics of chemoresistance. The PDX was treated in parallel with four chemotherapies for five iterative cycles. Exome sequencing identified few genes with de novo or enriched mutations in common among the different therapies, whereas many common depleted mutations/ genes were observed. Analysis of somatic mutations from The Cancer Genome Atlas (TCGA) supported the prognostic relevance of the identified genes. A mutation in TCF4 was found de novo in all treatments, and analysis of drug sensitivity profiles across cancer cell lines supported the link to chemoresistance. Loss of TCF4 conferred chemoresistance in breast cancer cell models, possibly by altering cell cycle regulation. Targeted sequencing in chemoresistant tumors identified an intronic variant of TCF4 that may represent an expression quantitative trait locus associated with relapse outcome in TCGA. Immunohistochemical studies suggest a common loss of nuclear TCF4 expression post-chemotherapy. Together, these results from tumor xenograft modeling depict a link between altered TCF4 expression and breast cancer chemoresistance.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available